Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01157091 · ClinicalTrials.gov registry record · Phase 2
Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
A Phase 2 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT01157091 is a Phase 2 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer that has completed, run by City of Hope Medical Center. The registered enrollment target is 28 participants, below the 203-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT01157091, a Phase 2 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well pazopanib hydrochloride works in treating patients with stage IV kidney cancer.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER immunologic technique
- DRUG pazopanib hydrochloride
Study Locations (2)
California
- City of Hope - Duarte
- South Pasadena Cancer Center - Pasadena
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2010-12-08 |
| Est. Completion | 2013-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01157091
The ClinicalTrials.gov registry entry for NCT01157091 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 203-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (86% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01157091 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01157091 about?
NCT01157091 is a clinical study titled "Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer". RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well pazopanib hydrochloride works in treating patients with stage IV kidney cancer.
What is the current status of trial NCT01157091?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2010-12-08. Estimated completion is 2013-12-31.
What conditions does trial NCT01157091 study?
This clinical trial studies the following conditions: Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer.
What interventions are being tested in trial NCT01157091?
The interventions under investigation include: laboratory biomarker analysis (OTHER), immunologic technique (OTHER), pazopanib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01157091?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01157091 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clear Cell Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
RECRUITING · Phase 2
-
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
RECRUITING · Phase 2
-
Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
RECRUITING · Phase 2
-
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Clear Cell Renal Cell Carcinoma
All registered trials for this condition
Stage IV Renal Cell Cancer
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.